Wellington Management Group LLP Makes New $802,000 Investment in Trevi Therapeutics, Inc. $TRVI

Wellington Management Group LLP acquired a new position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 127,452 shares of the company’s stock, valued at approximately $802,000. Wellington Management Group LLP owned approximately 0.13% of Trevi Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Two Sigma Investments LP bought a new stake in Trevi Therapeutics during the 4th quarter worth approximately $560,000. Ameriprise Financial Inc. increased its holdings in Trevi Therapeutics by 187.0% during the 4th quarter. Ameriprise Financial Inc. now owns 96,784 shares of the company’s stock worth $399,000 after purchasing an additional 63,067 shares in the last quarter. Vontobel Holding Ltd. bought a new stake in Trevi Therapeutics during the 1st quarter worth approximately $197,000. Renaissance Technologies LLC increased its holdings in Trevi Therapeutics by 42.0% during the 4th quarter. Renaissance Technologies LLC now owns 100,400 shares of the company’s stock worth $414,000 after purchasing an additional 29,700 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in Trevi Therapeutics by 11.3% during the 4th quarter. Northern Trust Corp now owns 482,815 shares of the company’s stock worth $1,989,000 after purchasing an additional 49,173 shares in the last quarter. 95.76% of the stock is owned by institutional investors.

Trevi Therapeutics Trading Up 0.7%

Trevi Therapeutics stock opened at $7.26 on Tuesday. Trevi Therapeutics, Inc. has a 12 month low of $2.36 and a 12 month high of $8.78. The business’s 50 day simple moving average is $6.95 and its 200 day simple moving average is $6.32. The company has a market cap of $884.12 million, a price-to-earnings ratio of -17.29 and a beta of 0.71.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01. As a group, equities research analysts forecast that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on TRVI shares. Cantor Fitzgerald started coverage on Trevi Therapeutics in a research note on Tuesday, July 1st. They issued an “overweight” rating and a $25.00 target price on the stock. Morgan Stanley started coverage on Trevi Therapeutics in a research note on Thursday, August 21st. They issued an “overweight” rating and a $18.00 target price on the stock. HC Wainwright started coverage on Trevi Therapeutics in a research note on Wednesday, May 28th. They issued a “buy” rating and a $21.00 target price on the stock. Raymond James Financial cut their target price on Trevi Therapeutics from $29.00 to $27.00 and set a “strong-buy” rating on the stock in a research note on Friday, August 8th. Finally, Wall Street Zen downgraded Trevi Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, June 6th. Two analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $20.11.

Trevi Therapeutics Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.